Kang, Yoon-Koo http://orcid.org/0000-0003-0783-6583
Qin, Shukui
Lee, Keun-Wook
Oh, Sang Cheul
Kim, In-Ho
Kim, Jong Gwang
Li, Yong
Yan, Zhuchen
Li, Jin
Bai, Li-Yuan
Chan, Catherine
Yusuf, Akeem
Zahlten-Kümeli, Anita
Taylor, Kate
Yamaguchi, Kensei
Funding for this research was provided by:
Amgen
Article History
Received: 29 March 2024
Accepted: 22 May 2024
First Online: 11 June 2024
Declarations
:
: Yoon-Koo Kang: Consulting fees (self): Amgen, Novartis, Roche, Daehwa, Zymeworks, Blueprint, Surface Oncology, ALX Oncology, Macrogenics, BMS, Merck, Liscure. Shukui Qin: None to disclose. Keun-Wook Lee: All support for the present manuscript: Five Prime Therapeutics; Grants or contracts from any entity: All to institution for conducting clinical trials—AstraZeneca, Ono pharmaceutical, Merck Sharp and Dohme, Merck KGaA, Roche, Pfizer, Beigene, Leap therapeutics, ALX Oncology, Zymeworks, Astellas, Macrogenics, Amgen, Seagen, Bolt therapeutics, Trishula therapeutics, Oncologie, Pharmacyclics, MedPacto, Green Cross Corp, ABLBIO, Y-BIOLOGICS, Daiichi Sankyo, Taiho Pharmaceutical, InventisBio, Elevar Therapeutics, Metafines, Idience, Genome & Company, Exelixis; Honoraria for lectures: Ono pharmaceutical, Boryung, Daiichi Sankyo, Astellas, Sanofi-Aventis; Participation on a Data Safety Monitoring Board or Advisory Board: ALX Oncology, Metafines. Sang Cheul Oh: None to disclose. In-Ho Kim: None to disclose. Jong Gwang Kim: None to disclose. Yong Li: None to disclose. Zhuchen Yan: None to disclose. Jin Li: Research Grants: Roche; Speakers Bureau: Eli Lilly, AstraZeneca. Li-Yuan Bai: None to disclose. Catherine Chan: Employee and stockholder, Amgen Inc. Akeem Yusuf: Employee and stockholder, Amgen Inc. Anita Zalten-Kümeli: Employee and stockholder, Amgen Inc. Kate Taylor: Employee and stockholder, Amgen Inc. Kensei Yamaguchi: Research Grants: Taiho Pharm; Speakers Bureau: Daiichi Sankyo Co., Ltd.,Chugai Pharmaceutical Co., Ltd.,Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Merck Biopharm Co., Ltd.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.